| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, develops novel allosteric ion channel modulators for patients with serious central nervous system disorders in Australia. Its lead product candidate is BNC210, an oral, proprietary, selective negative allosteric modulator of the alpha7 nicotinic acetylcholine receptor for post-traumatic stress disorder. The company also develops Merck alpha7 positive allosteric modulators. It has a research collaboration and license agreement with Merck & Co., Inc. to develop alpha7 …
Over the last 12 months, insiders at Neuphoria Therapeutics Inc. have bought $0 and sold $0 worth of Neuphoria Therapeutics Inc. stock.
On average, over the past 5 years, insiders at Neuphoria Therapeutics Inc. have bought $3.28M and sold $0 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 639,110 shares for transaction amount of $3.28M was made by Lynx1 Capital Management LP (10 percent owner) on 2025‑10‑21.
| Lynx1 Capital Management LP | 10 percent owner | 875328 16.1758% | $2.62M | 1 | 0 | <0.0001% |
| Increased Positions | 19 | +237.5% | 1M | +675.71% |
| Decreased Positions | 3 | -37.5% | 18,847 | -9.65% |
| New Positions | 9 | New | 1M | New |
| Sold Out Positions | 2 | Sold Out | 18,331 | Sold Out |
| Total Postitions | 24 | +200% | 1M | +666.06% |